The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2024 | CAR-Ts in multiple myeloma: their current role and the future
Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, provides an overview of CAR T-cell therapy in treating myeloma. The currently approved CAR-T therapies, ide-cel and cilta-cel, have shown impressive progression-free survival (PFS) and overall response rates (ORR) in the KarMMa (NCT03361748) and CARTITUDE-1 (NCT03548207) trials, respectively. Dr Einsele predicts CAR-Ts will be used earlier in treatment based on results from the CARTITUDE-4 trial (NCT04181827), as early T-cell extraction and less pretreatment enhance their efficacy. Research is also exploring targeting different antigens like BCMA and GPRC5D to counteract antigen loss in myeloma cells, and combining CAR-Ts with other agents to boost their effectiveness. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: GlaxoSmithKline, Sanofi, Takeda, Amgen, Novartis, Janssen, Bristol Myers Squibb/Celgene; Consulting or advisory role: GlaxoSmithKline, Sanofi, Takeda, Amgen, Novartis, Janssen, Bristol Myers Squibb/Celgene; Travel support: GlaxoSmithKline, Sanofi, Takeda, Amgen, Novartis, Janssen, Bristol Myers Squibb/Celgene; Research Funding: GlaxoSmithKline, Sanofi, Takeda, Amgen, Novartis, Janssen, Bristol Myers Squibb/Celgene.
